New Frontiers in Osteoporosis: Targets in Bone Remodeling
New Frontiers in Osteoporosis: Targets in Bone Remodeling
Sunday, April 3, 2016 | 5:45 – 8:00 AM EST
Renaissance Boston Waterfront Hotel, Pacific Ballroom
This course is a live CME-certified ancillary symposium presented at ENDO 2016, the Endocrine Society's 98th Annual Meeting and Expo, held in Boston, Massachusetts, April 1–4, 2016. ENDO 2016 ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC). There is no cost to attend, and all ENDO 2016 attendees are welcome; however, seating is limited and advance registration is recommended. You must be registered for ENDO 2016 to attend an ENDO 2016 ancillary symposium.
This activity is supported by an educational grant from Amgen, Inc. and Merck & Co., Inc.
Opening and Welcome
Program Director: Michael R. McClung, MD – Oregon Osteoporosis Center
Update on Current State of Osteoporosis Therapy
Paul D. Miller, MD – University of Colorado Health Sciences Center
Cathepsin K Inhibitors as an Emerging Antiresorptive
Bente Langdahl, PhD, DMSc – Aarhus University Hospital (Denmark)
New Variations of Parathyroid Hormone
Benjamin Z. Leder, MD – Massachusetts General Hospital
Sclerostin Antibodies at the Frontier
Michael R. McClung, MD – Oregon Osteoporosis Center
Moderated Panel Discussion and Audience Questions
This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, and healthcare professionals who treat patients with bone disorders.
Upon completion of this educational activity, participants will be better able to:
- Summarize current insights in the pathways that regulate bone remodeling and the underlying pathophysiology of osteoporosis
- Assess patients for osteoporosis and apply current state of care methods taking known limitations into consideration
- Discuss the mechanism of action and current findings of new and emerging osteoporosis therapies
- Recognize the benefits, limitations of on new and emerging osteoporosis therapies, and potential impact of ongoing trials on practice
Michael R. McClung, MD – Program Director
Director, Oregon Osteoporosis Center
Paul D. Miller, MD
Distinguished Clinical Professor of Medicine
University of Colorado Health Sciences Center
Colorado Center for Bone Research
Bente Langdahl, PhD, DMSc
Professor and Consultant
Department of Endocrinology and Internal Medicine THG
Aarhus University Hospital
Benjamin Z. Leder, MD
Associate Professor of Medicine
Massachusetts General Hospital
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Bente Langdahl, PhD: Advisory Group Member and Clinical Researcher, Amgen, Eli Lilly & Company, Merck & Co.; Researcher, Novo Nordisk
Benjamin Z. Leder, MD: Advisory Group Member and Clinical Researcher, Amgen, Lilly USA, LLC; Advisory Group Member, Merck & Co.
Michael R. McClung, MD: Scientific Board Member and Speaker, Amgen; Scientific Board Member, Merck & Co.
The following faculty reported no relevant financial relationships: Paul D. Miller, MD
The following SPC member who planned and/or reviewed content for this activity reported relevant financial relationships:
E. Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck
The following SPC Committee members reported relevant financial relationships:
Zahid Ahmad, MD: Consultant, Regeneron; Speaker, Amgen, Genzyme
Sarah Berga, MD: Advisory Board, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.
Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk
Irl Hirsch, MD: Consultant, Abbott Laboratories, Johnson & Johnson, Roche Diagnostics, Valeritas; Investigator, Sanofi
Lisa Nachtigall, MD: Consultant, Genentech; Consultant and Principal Investigator, Ipsen
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals
Guillermo E. Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron
The following SPC members reported no relevant financial relationships: John Carmichael, MD; Natalie Cusano, MD; Larry Fox, MD; Alan Kelly, MD; Michael S. Irwig, MD; Connie B. Newman, MD
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
- 2.00 AMA PRA Category 1 Credits™
- 2.00 CME Certificate of Participation